Cargando…
Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience
BACKGROUND: Cinacalcet is a calcimimetic approved in adults with primary hyperparathyroidism (PHPT). Few cases reports described its use in pediatric HPT, with challenges related to the risk of hypocalcemia, increased QT interval and drug interactions. In this study, we report the French experience...
Autores principales: | Bernardor, Julie, Flammier, Sacha, Salles, Jean-Pierre, Amouroux, Cyril, Castanet, Mireille, Lienhardt, Anne, Martinerie, Laetitia, Damgov, Ivan, Linglart, Agnès, Bacchetta, Justine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449487/ https://www.ncbi.nlm.nih.gov/pubmed/36090548 http://dx.doi.org/10.3389/fped.2022.926986 |
Ejemplares similares
-
Intermittent Bi-Daily Sub-cutaneous Teriparatide Administration in Children With Hypoparathyroidism: A Single-Center Experience
por: Bernardor, Julie, et al.
Publicado: (2021) -
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020) -
Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011) -
Hypertension in Children and Adolescents: A Position Statement From a Panel of Multidisciplinary Experts Coordinated by the French Society of Hypertension
por: Bouhanick, Béatrice, et al.
Publicado: (2021) -
Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)